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http://dx.doi.org/10.1016/j.ccell.2015.08.002SUMMARYLY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers
in RAF dimers. Biochemical and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF
isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared
to their BRAF activities. LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of
downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF hetero-
dimers. Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including
BRAF or CRAF homodimers. Due to these unique properties, LY3009120 demonstrates minimal paradoxical
activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models
carrying KRAS, NRAS, or BRAF mutation.INTRODUCTION
Gain-of-function mutations that lead to constitutive activation of
the RAS-RAF-MEK-MAPK cascade are among themost common
mutations in cancers. RAS mutation was initially identified in the
early 80s (Der et al., 1982). Through decades of research, RAS
mutations have been identified in 30% of human cancers and
demonstrated to activate multiple signaling pathways (Cox et al.,
2014; Pylayeva-Gupta et al., 2011). Because RAF proteins are
critical downstream effectors of RAS signaling, early efforts were
focused ondevelopingRAF inhibitors for treatment ofRASmutant
cancers. These efforts fell short of the intended goal, but led to
the identification of sorafenib, a multi-kinase inhibitor with weak
RAF activity while possessing potent activities against VEGFR2,
PDGFR,andother receptor tyrosinekinases (Escudieretal., 2007).Significance
Vemurafenib and dabrafenib promote paradoxical pathway act
RAS mutation due to their ineffective inhibition of the active R
CRAF isoforms and bind to both protomers of RAF dimers, t
LY3009120 induces minimal paradoxical activation, inhibits
in vitro and in vivo in cancer models carrying oncogenic K
LY3009120 has the potential for treatment of cancer patients w
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pathway in mediating tumor growth signals from RAS is contex-
tual and not fully understood. It was shown that the RAF proteins
function as dimers in tumors harboring RASmutations (Freeman
et al., 2013; Rajakulendran et al., 2009; Weber et al., 2001). In
these tumors, the RAF-MAPK pathway is often, but not always,
constitutively active. Even when active, pharmacological inter-
vention with MAPK pathway inhibitors can have a range of
outcomes, from potent inhibition to no detectable effect on cell
proliferation (Halilovic et al., 2010; Lamba et al., 2014; Lito
et al., 2014; Pratilas et al., 2008; Solit et al., 2006; Wee et al.,
2009). Clinically, MEK1/2 inhibitors have been effective in
BRAF mutant melanoma (Flaherty et al., 2012). However, they
are generally less effective inKRASmutant tumors, a result reca-
pitulated in vitro using panels of KRAS and BRAF mutant cellsivation and are contraindicated for treatment of cancers with
AF dimers. LY3009120 is able to inhibit ARAF, BRAF, and
hus effectively inhibiting active RAF dimers. Consequently,
MEK phosphorylation, and exhibits anti-tumor activities
RAS, NRAS, or BRAF mutations. The data suggest that
ith KRAS, NRAS, or BRAF mutation.
c.
(Pratilas et al., 2008; Solit et al., 2006). Recent genetic knockout
studies have revealed the critical role of CRAF in oncogenic
KRAS-driven lung cancer (Blasco et al., 2011; Karreth et al.,
2011). RNAi-based screens have also demonstrated that sup-
pression of CRAF augments the inhibitory activity of MEK inhib-
itors (Lamba et al., 2014; Lito et al., 2014). These studies suggest
that inhibition of CRAF can provide a useful therapeutic strategy
in RAS mutant tumors.
BRAFmutationswere discovered in 66%ofmelanoma (Davies
et al., 2002). It was shown thatBRAF V600E is a potent oncogene
that activates the MAPK pathway and functions as a monomer
(Davies et al., 2002; Poulikakos et al., 2011; Roring et al., 2012;
Wan et al., 2004). The discovery of BRAF mutations spawned a
new wave of drug discovery efforts. This work culminated in the
Food and Drug Administration (FDA) approval of BRAF-selective
inhibitors vemurafenib and dabrafenib. Both showed anti-tumor
activities in BRAF mutant xenograft models (Bollag et al., 2010,
2012; King et al., 2013; Yang et al., 2010) and significant benefit
among BRAF mutant melanoma patients (Chapman et al.,
2011; Flaherty et al., 2010; Hauschild et al., 2012). However,
both also induced dimerization of RAF proteins and promoted
paradoxical activation in BRAF wild-type (WT) cells (Hatzivassi-
liou et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2010).
This compound-induced paradoxical activation involves an
asymmetric RAF dimer in which one of the two ATP sites cannot
be effectively occupied by the drug. It has also been suggested
that paradoxical activation is a consequence of the relief of
inhibitory autophosphorylation of the P loop of the CRAF proto-
mer by selective occupancy of BRAF inhibitors (Holderfield
et al., 2013). The paradoxical activation is thought to explain
the increased tumor growth andmetastasis observedwith selec-
tive BRAF inhibitors in preclinical models (Hatzivassiliou et al.,
2010; Sanchez-Laorden et al., 2014) and skin side effects in clinic
(Chapman et al., 2011; Hauschild et al., 2012). Therefore, vemur-
afenib and dabrafenib are contraindicated for treatment of can-
cer patients with BRAFWT status. We hypothesize that in order
to effectively inhibitRASmutant cancer cells and suppress para-
doxical activation, it is important for RAF inhibitors to have potent
inhibitory activities against all RAF isoforms, occupy theATPsites
of both protomers and inhibit the dimer activity. The goal of this
study is to develop and characterize such inhibitors.
RESULTS
Discovery of Pan-RAF and RAF Dimer Inhibitor
LY3009120
As part of our discovery effort, we have identified a pan-RAF in-
hibitor LY3009120, 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-
5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)
urea (Figure 1A) (Henry et al., 2015). The crystal structure of
BRAF in complex with LY3009120 determined at the resolution
of 2.70 A˚ revealed a side-to-side dimeric arrangement of the pro-
tein with the inhibitor bound to both protomers (Figures 1B and
1C; Table S1). The simultaneous binding to two sites of the dimer
makes LY3009120 distinct from vemurafenib, which occupies
only one of two ATP-binding sites (Figure S1A) (Bollag et al.,
2010, 2012). In the crystal structure of LY3009120, the BRAF
protein is in the inactive DFG-out/aC-helix-in conformation (Fig-
ure 1B). The pyridopyrimidine scaffold binds to the hinge-bindingCanregion of the ATP pocket, forming bidentate hydrogen-bonding
interactions with Cys532. Other regions of LY3009120 make
interactions with kinase residues outside of the ATP pocket.
The pyridine ring utilizes aromatic edge-to-face (T-shape) inter-
actions with the side chain of Phe595 as well as van-der-Waals
contacts with Val471. The central phenyl ring makes interactions
with the gatekeeper Thr529 and Lys483 side chains, positioning
two nitrogen atoms of the inhibitor urea moiety within a
hydrogen-bond distance to Glu501 of the aC-helix while the
carbonyl group interacts with Asp594-N of the DFG region. A
back pocket of the kinase, which serves as a cognate switch
pocket for Phe595 is intercepted by the distal butyl side chain.
In composite, these interactions stabilize the DFG-out/aC-helix-
in type IIa conformation of the kinase.
LY3009120 Is a Pan-RAF Inhibitor of RAF Isoforms
In biochemical assays, LY3009120 inhibited BRAF WT, CRAF
WT, BRAFV600E, and BRAFV600E+G468A with the IC50 values
of 9.1, 15, 5.8, and 17 nM, respectively. While vemurafenib
inhibited BRAF WT, BRAFV600E and BRAFV600E+G468A with
IC50 values of 32, 6.1, and 22 nM, respectively, it was less effec-
tive against CRAF with IC50 of 414 nM in our assays (Figure 1D).
The affinity of LY3009120 to three RAF isoforms was further veri-
fied in the whole cell-based KiNativ assay (Patricelli et al., 2011).
In this assay, LY3009120 was incubated with whole cell lysates
and its binding affinities to native RAF isoforms and other kinases
were determined using a mass spectrum-based technology. As
summarized in Figure 1E, LY3009120 bound to ARAF, BRAF,
and CRAF proteins with similar affinities of 44, 31–47, and
42 nM, respectively. Vemurafenib was able to bind to BRAF
and ARAF with the IC50 values of 260–360 and 950 nM, respec-
tively. However, its binding affinity to CRAF was >10,000 nM.
Dabrafenib bound to BRAF and ARAF with IC50 of 6 and
26 nM, respectively, while its binding affinity to CRAF displayed
an IC50 of 150 nM, 25-fold less than BRAF. In a final biochem-
ical study, we immunoprecipitated (IP) native RAF proteins and
measured their kinase activities usingMEK1 kinase dead protein
as a substrate. As demonstrated in Figure 1F, both LY3009120
and vemurafenib inhibited the kinase activity of IP-prepared
BRAF mutant protein with LY3009120 being more potent. In
the same A375 cell lysates, the CRAF protein was also prepared
by IP, and LY3009120 inhibited CRAF kinase activity in a dose-
dependent manner from 0.1–10 mM, while vemurafenib had min-
imal CRAF activity up to 10 mM (Figure S1B). Similarly, an IP and
kinase assay for CRAF protein was also conducted in NRAS
mutant SKMel-2 and KRAS mutant HCT116 cells. In both cell
lines, CRAF IP produced CRAF native protein with no detectable
BRAF protein as revealed by western blot analysis. LY3009120
inhibited the kinase activity of CRAF in a dose-dependent
manner, whereas vemurafenib showed minimal inhibition (Fig-
ures 1G and 1H). Overall, the biochemical, whole-cell KiNativ
and IP kinase assays consistently show that LY3009120 is an
inhibitor of three RAF isoforms.
LY3009120 is relatively selective against a broader panel of
protein kinases. Among over 170 kinases measured by KiNativ
assays, six other proteins, p38, EphA2, EphB4, MAP3K1, FYN,
and ZAK have binding affinities %100 nM, seven targets, JNK,
MAP2K5, ABL, CSK, GCN2, IRAK1, and SRC have binding affin-
ity between 290–1,000 nM (Table S2). The remaining kinasescer Cell 28, 384–398, September 14, 2015 ª2015 Elsevier Inc. 385
Figure 1. Inhibitory Activities of LY3009120 against RAF Isoforms
(A) Chemical structure of LY3009120.
(B) View of the binding mode of LY3009120 in the BRAF crystal structure determined at the resolution of 2.7 A˚. The inhibitor molecules and protein residues are
shown as sticks and colored in the following atom colors: carbon (LY3009120) green; carbon (BRAF) brown; nitrogen, blue; oxygen, red; sulfur, yellow; fluorine,
light green. Molecular interaction surface is generated with the MOE program (Chemical Computing Group, CCG) and colored by lipophilicity (hydrophilic areas
are in magenta; lipophilic areas are in green; neutral areas in white).
(C) Ribbon representation of the BRAF homodimer in a complex with LY3009120 as indicated by black arrows.
(D) In vitro biochemical activities of LY3009120 and vemurafenib against RAF isoforms and their mutations.
(E) Binding affinities of LY3009120, vemurafenib, and dabrafenib to ARAF, BRAF, and CRAF full-length proteins in KiNativ whole cell assays, see Experimental
Procedures for details.
(legend continued on next page)
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(over 150 examined) are inactive at 1 mM (Table S3). Conven-
tional kinase assays with purified proteins also confirmed the
inhibitory activities of LY3009120 to some of these targets (Table
S2). Other protein kinases inhibited in purified kinase assays
include DDR2 (210 nM), FLT3 (385 nM), Kit (145 nM), PDGFRa
(67 nM), and PDGFRb (384 nM). The cellular activities of these
targets were not yet verified.
LY3009120 Induces RAF Dimerization but Inhibits the
Kinase Activity of the Induced Dimers
In KRAS mutant HCT116 cells, we demonstrated that
LY3009120 induced BRAF/CRAF heterodimerization. As illus-
trated in Figure 2A by IP of either BRAF or CRAF and western
blot analysis, treatment of HCT116 cells with 0.01, 0.1, or 1 mM
of LY3009120 induced a dose-dependent BRAF/CRAF heterodi-
merization. This same heterodimerization was also induced by
10 mMof vemurafenib, 2 mMof dabrafenib, or 10 mMof sorafenib,
although the potency and magnitude of the RAF dimerization
induced by these RAF inhibitors were different. As demonstrated
in Figure 2B, LY3009120 inhibited phosphorylation of MEK and
ERK from 0.01–1.0 mM in spite of its promotion of BRAF/CRAF
heterodimer. However, vemurafenib at 10 mM promoted phos-
phorylation of MEK and ERK, and dabrafenib at 2 mM showed
no inhibition of phospho-MEK or -ERK (Figure 2B). The same
results were also confirmed in H358, a lung cancer cell line
with a KRAS mutation (Figures S2A and S2B).
To further evaluate RAF inhibitor-induced dimerization, we
established luciferase complementation assays as described
(Ozawa et al., 2001). In these assays, the luciferase was split
into the C- and N-terminal portions that were then separately
fused to the two RAF proteins. The luciferase activity was recon-
stituted if compound-induced dimerization occurred. Utilizing
this technology, we developed stable HCT116 and HEK293
cell lines by transfection of BRAF/CRAF or CRAF/CRAF con-
structs. As illustrated in Figures 2C and S2C, LY3009120
and other RAF inhibitors (vemurafenib, dabrafenib, sorafenib,
AZ628, and TAK-632) all induced BRAF/CRAF heterodimers
and CRAF homodimers. However, the potency and magnitude
of RAF inhibitor-induced dimer formation were different.
LY3009120 induced themost significant RAF dimerization. How-
ever, a key difference among these RAF inhibitors is their ability
to inhibit the downstream signaling in these assays. As shown in
Figures 2D and S2D, LY3009120 inhibited phospho-ERK in a
dose-dependent manner in all dimerization systems. Whereas
dabrafenib, a more potent BRAF inhibitor, also induced dimer
formation in all assays, yet had paradoxical activation in the
same concentration ranges tested. These results further confirm
that LY3009120 is able to inhibit the activities of BRAF/CRAF
heterodimers and CRAF homodimers. Additionally, a type I
RAF inhibitor, SB590885, also induced significant BRAF/CRAF
heterodimer and CRAF/CRAF homodimer (Figure S2E). How-
ever, in contrast with LY3009120, it promoted paradoxical acti-
vation in RAS mutant cells (Figures S2F and S2G).(F) BRAF kinase inhibitory activities of LY3001920 and vemurafenib. The BRAF kin
length MEK1 as the substrate.
(G and H) The CRAF kinase assay was conducted with CRAF IP from NRAS mu
See also Figure S1 and Tables S1, S2, and S3.
CanTo assess why LY3009120 induced more significant RAF
dimerization than vemurafenib or dabrafenib, we postulate
that the binding mode of a RAF inhibitor may affect protein
dimerization. Structural analysis revealed that inhibitors that
bind to the kinase in the aC-helix-in conformation (such as
type I inhibitor SB590885 and type IIa inhibitors LY3009120,
AZ628, and TAK-632) stabilize the side-to-side dimeric arrange-
ment (Figure S2H). In contrast, binding of type IIb inhibitors
(such as vemurafenib or dabrafenib) causes movement of the
aC-helix to the out orientation that disfavors the dimer formation
by disrupting the Arg506-Asp449 salt bridge and positioning
positively-charged Arg506 from the other protomer in the dimer
(Figure S2H).
LY3009120 inhibits the Kinase Activities of Pre-formed
RAF Dimers
To further evaluate the inhibitory activities against RAF dimers
that were not induced by a RAF inhibitor, two additional methods
were developed. We transfected HEK293 cells with a Flag-
tagged BRAF E586K and a GFP-tagged CRAF E478K that were
demonstrated to promote dimer formation (Freeman et al.,
2013; Rajakulendran et al., 2009; Roring et al., 2012). As illus-
trated in Figure 3A, transfected HEK293 cells had enhanced ac-
tivities of phospho-MEK and -ERK, an indication of dimer forma-
tion and RAF activation. Importantly, LY3009120 inhibited the
enhanced phospho-MEK and -ERK activities in a dose-depen-
dent manner, while vemurafenib was inactive in these cells. As
a control, we also transfected HEK293 cells with a Flag-tagged
BRAFR509HandaGFP-taggedCRAFR401H,whichcarriedmu-
tations in the interface of RAF dimers that were demonstrated to
disrupt the dimer formation of RAF proteins. Indeed, these trans-
fections induced minimal increase of phospho-MEK and -ERK
levels (Figure 3A, right panel). In a separate study, we transfected
a BRAF splice variant, p61BRAF (BRAF V600E with a deletion of
amino acids 169–380) into A375 cells. P61BRAFwas identified to
be a major mechanism of vemurafenib resistance by acting as a
RAS-independent BRAF homodimer (Poulikakos et al., 2011). As
demonstrated in Figure S3, we established many stable clones
of A375 cells with p61BRAF overexpression, and selected clone
number 5 for further studies. In A375 cells, both LY3009120
and vemurafenib showed a dose-dependent inhibition of phos-
pho-MEK, -ERK, and -RSK (Figure 3B). However, in p61BRAF-
transfected A375 cells, vemurafenib was inactive up to 10 mM,
whereas LY3009120 showed a dose-dependent inhibition of
MAPK signaling (Figure 3C), suggesting that LY3009120 was
able to inhibit the BRAF homodimer.
LY3009120 Inhibits Phospho-MEK and -ERK in RAS or
BRAF Mutant Cells and Induces Minimal Paradoxical
Activation in RAS Mutant Cells
In melanoma A375 and colorectal Colo205 cells (Figure 4A)
with BRAF V600E mutation, LY3009120, vemurafenib, and dab-
rafenib all inhibited the phosphorylation ofMEK and ERK. Amongase assay was conducted with BRAF IP from A375 cells and a kinase dead full
tant SK-Mel2 cells (G) or KRAS mutant HCT116 cells (H).
cer Cell 28, 384–398, September 14, 2015 ª2015 Elsevier Inc. 387
Figure 2. LY3009120 Induces RAF Dimerization but Inhibits the Kinase Activities of the Induced Dimers
(A) HCT116 cells were initially treated with individual RAF inhibitor in the concentrations indicated, the cell lysates were used for IP and western blot analysis.
(B) Western blot analysis of the indicated proteins in total cell lysates in compound-treated cells used in (A).
(C) HCT116 cells were transfected with the N-terminal half of luciferase fused to BRAF or CRAF, as indicated, together with the C-terminal half of luciferase fused
to CRAF. The reconstituted luciferase activity was measured as described in Supplemental Experimental Procedures.
(D) Immunoblot analysis of indicated molecules in cell lysates prepared from cells used in (C).
See also Figure S2.
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Figure 3. LY3009120 Inhibits the Kinase
Activities of RAF Dimers
(A) Immunoblot analysis of indicated molecules
in control HEK293 cells (left) or HEK293 cells
transfected with BRAF E586K and CRAF E478K
(middle) or with BRAF R509H and CRAF R401H
(right) and treated with LY3009120 or vemurafenib.
(B) Phospho-MEK, -ERK, and -RSK inhibition by
LY3009120 or vemurafenib in A375 cells.
(C) Phospho-MEK, -ERK, and -RSK inhibition by
LY3009120 or vemurafenib in A375 cells trans-
fected with p61BRAF spliced variant.
See also Figure S3.them, dabrafenib was the most and vemurafenib was the
least potent BRAF V600E inhibitor. However, in NRAS or KRAS
mutant tumor cells, the inhibitors showed distinct effects. In
three RAS mutant cells (NRASQ61K melanoma SK-Mel30,
KRASQ61K lung Calu6, and KRASG13D colorectal HCT116
cells), vemurafenib promoted a dose-dependent increase of
phospho-MEK and -ERK. Dabrafenib induced significant phos-
pho-MEK and -ERK activation at concentrations up to 1 mM
and inhibited the phospho-MEK and -ERK at a high concentra-
tion of 10 mM. LY3009120 showed a dose-dependent inhibition
of phospho-MEK and -ERK in all three RASmutant cells without
notable pathway activation (Figure 4B). To further define the par-
adoxical activation, we did a lower dose titration study of
LY3009120 from 0.0003 to 10 mM in KRASmutant HCT116 cells
and NRAS mutant SK-Mel30 cells (Figure 4C). LY3009120
induced minor increases of phospho-MEK or -ERK at very low
concentrations, confirming that LY3009120 induced minimal
paradoxical activation in RAS mutant cells.
LY3009120 Is Active against Tumor Cells with BRAF or
RASMutation as well as Vemurafenib-Resistant
Melanoma Cells
LY3009120 inhibited the proliferation of melanoma cells with
either BRAF or NRAS mutation (Tables 1 and S4). For NRAS
mutant cells, the IC50 values were 25 to 249 nM, and for BRAF
mutant cells, the IC50 values were 15 to 53 nM, with the excep-
tion of A2508 cells, which are partially resistant to LY3009120
likely due to a co-occurring PTEN mutation. In the same assay
conditions, vemurafenib was only effective in inhibiting the
growth of BRAF mutant cells (Table S4). To further compare
the activities of LY3009120 and vemurafenib in melanoma cells,Cancer Cell 28, 384–398, Sewe tested them in a panel of 25melanoma
cell lines mostly consisting of patient-
derived xenograft (PDX) cells from Oncot-
est in three-dimensional soft agar assays.
Again, LY3009120 was generally active
against melanoma cells with either BRAF
or NRAS mutation, similar to MEK inhibi-
tor selumetinib (Table 1). However, ve-
murafenib was generally active only for
BRAFmutant, but notNRASmutant cells.
We previously generated and charac-
terized vemurafenib-resistant melanoma
cell lines, A375-R1, A375-R2, and A375-R4 with different resistant mechanisms (Yadav et al., 2012,
2014). In A375-R1 cells, the resistant mechanism was due to
RTK and RAS activation leading to MAPK reactivation. BRAF
spliced variant (p61BRAF) and NRAS Q61K mutation were
confirmed resistant mechanisms in A375-R2 and R4 cells,
respectively (Yadav et al., 2012, 2014). Although all these three
cells are resistant to vemurafenib and dabrafenib, they are sen-
sitive to LY3009120 with IC50 values of 10.8, 24, and 56 nM,
respectively, suggesting that LY3009120 may have the potential
of overcoming BRAF resistance (Table S4).
Wealsomeasured the anti-proliferative activities of LY3009120
across a panel of genetically characterized cancer cell lines.
LY3009120 and BRAF-selective inhibitors exhibit potent inhibi-
tion for growth of most BRAF V600Emutant tumor cells, particu-
larly melanoma cells (Figure 5A; Table S5). To identify additional
molecular determinants of sensitivity to LY3009120, statistical
methods were employed to identify features that best associate
with its tumor cell panel profile. The association between muta-
tions in well characterized cancer genes and the response to
LY3009120 were tested using a Tobit regression approach
(Tobin, 1958). As shown in Figure 5A, tumor cells with a mutation
in either BRAF or any of the three RAS genes scored as the most
significantly associated with response to LY3009120. Cells with
mutations in BRAF, NRAS, or KRAS are significantly more sensi-
tive to LY3009120.Mutations inRB1 (false discovery rate [FDR] =
0.005), PIK3CA (FDR = 0.06), TP53 (FDR = 0.06), and VHL (FDR =
0.06) predict resistance to LY3009120. To more closely explore
differences in antitumor activity between clinically approved
selective BRAF inhibitors and LY3009120, we tested dabrafenib
and vemurafenib across a subset of the same cell panel to
compare their profiles.BRAFmutation is a statistically significantptember 14, 2015 ª2015 Elsevier Inc. 389
Figure 4. LY3009120 Induces Minimal Paradoxical Pathway Activation
(A) Phospho-MEK and -ERK inhibition by LY3009120, vemurafenib or dabrafenib in BRAF V600E mutant A375 and Colo-205 cells.
(B) Phospho-MEK and -ERK inhibition or stimulation by LY3009120, vemurafenib, or dabrafenib in NRAS mutant SK-Mel30, and KRAS mutant Calu6 and
HCT116 cells.
(C) Low dose titration of LY3009120 to evaluate paradoxical activation of RAF in KRAS mutant HCT116 or NRAS mutant SK-Mel30 cells.
All compound treatment was 2 hr at 37C.predictor of sensitivity to all three compounds (FDR < 0.005), as
expected, but RAS mutations do not predict sensitivity to either
vemurafenib or dabrafenib (Table S5).
Activity Profiles of LY3009120 and MEK Inhibitor
Trametinib
We also tested MEK inhibitor trametinib in a subset of the same
cell panel, and trametinib and LY3009120 shared similar sensi-390 Cancer Cell 28, 384–398, September 14, 2015 ª2015 Elsevier Intivity profiles (Figure 5B; Table S5). Tumor cells with a mutation
in BRAF or any of the three RAS genes scored as the most
significantly associated with sensitivity to trametinib. Mutations
in RB1, PIK3CA, and PTEN predict resistance. One of the
unexpected discoveries in a comparison of trametinib and
LY3009120 was that, while their profiles were similar, several
cell lines weremore potently inhibited by LY3009120 than by tra-
metinib despite the fact that trametinib has a higher affinity for itsc.
Table 1. Anti-proliferation Activities of LY3009120,
Vemurafenib, and Selumetinib in Melanoma Cells in Soft Agar
Assays
Cells Mutation
IC50 (mM)
LY3009120 Selumetinib Vemurafenib
MEXF 1732 BRAF V600E 0.010 0.029 0.143
MEXF 1737 BRAF V600E 0.057 0.353 0.773
MEXF 1765 BRAF V600E 0.044 0.292 1.007
MEXF 1829 BRAF V600E 0.080 0.122 0.362
MEXF
HT-144
BRAF V600E 0.015 0.048 0.169
MEXF
HT-144
BRAF V600E 0.021 0.028 0.131
MEXF
SK-MEL-28
BRAF V600E 0.138 0.496 1.380
MEXF
SK-MEL-5
BRAF V600E 0.107 0.155 0.995
MEXF 462 BRAF V600E 0.046 0.098 0.378
MEXF 672 BRAF V600E 0.039 0.148 0.541
MEXF 989 BRAF V600E 0.107 0.248 0.995
MEXF 520 BRAF V600E 0.085 0.312 1.098
MEXF 1539 BRAF V600E 0.270 0.138 30.000
MEXF 276 BRAF V600E 0.446 0.440 9.220
MEXF 2095 TP53 D259Y 0.308 0.127 0.280
MEXF 2106 N/A 0.078 0.084 0.487
MEXF 394 N/A 0.112 0.259 1.519
MEXF 2090 NRAS Q61K, 0.384 0.173 0.281
MEXF 535 NRAS Q61K, 0.106 0.042 13.646
MEXF 1341 NRAS Q61K, 0.271 0.105 27.349
MEXF 1792 NRAS G13D 0.097 0.062 15.895
MEXF 622 NRAS Q61K,
BRAF G469R
0.229 1.045 13.497
MEXF 666 NRAS Q61L 0.941 0.805 16.005
MEXF 1870 NRAS R167L,
BRAF K601E,
A665V,
1.173 35.555 33.371
MEXF 274 MAP3K9
T598M
1.086 0.962 14.766
N/A, not available. See also Table S4.target (Table S5). For example, NCI-H1703, which is inhibited by
LY3009120 (IC50 = 0.085 mM), is known to have an amplification
of PDGFRA, and LY3009120 activity may derive, in part, from in-
hibition of PDGFRa kinase. The CML cell line K562, driven by the
BCR-ABL1 fusion, is also sensitive to LY3009120, despite lack-
ingRAF orRASmutations. LY3009120 did not have strong activ-
ity against ABL kinase suggesting that the anti-proliferative
effect is likely due to the inhibition of the downstream MAPK
pathway, and these cells may depend on RAF-MAPK signaling,
a result consistent with recent reports (Packer andMarais, 2011).
Both NCI-H1703 and K562 cell lines scored among the most
CRAF-dependent in our analysis of RNAi screening data (data
not shown). This supports the notion that the growth inhibition
of these cell lines by LY3009120may at least in part be attributed
to CRAF inhibition. Finally, cell line NCI-SNU-1 was very sensi-Cantive to LY3009120 but insensitive to MEK inhibitor. NCI-SNU-1
cells carry an unusual BRAF A400V mutation in addition to a
KRAS G12D mutation. Further investigations are ongoing to
elucidate the mechanism that explains this difference, but it
does suggest that LY3009120 is distinct from other clinically
approved drugs targeting the RAF/MAPK pathway.
To further differentiate LY3009120 from trametinib, we devel-
oped an A375 trametinib-resistant cell line using the method
described (Yadav et al., 2012). When A375 cells were treated
with increased concentrations of trametinib, significant resis-
tance was developed with IC50 increased from <1 nM in
parental cells to 884 nM in resistant cells (Figure 5C). However,
LY3009120 was still active against these resistant cells with
IC50 of 83 nM compared to its IC50 of 15 nM to the parental cells
(Figure 5D). Molecular analysis revealed that part of the trameti-
nib resistantmechanismwas the CRAF activation with enhanced
CRAF phosphorylation at S338 position (Figure 5E). This obser-
vation is consistent with a recent finding that trametinib is not
effective against CRAF-mediated MAPK activation (Lito et al.,
2014). Additionally, we also developed trametinib-resistant cells
by ectopic expression of P124SmutantMEK1 into A375 cells. As
shown in Figure S4A, expression of P124S mutant MEK1 led to
the resistance to trametinib, and LY3009120 was inactive to
these resistant cells (Figure S4B).
To evaluate the resistant mechanism of BRAF V600E
mutant melanoma to LY3009120, we also generated A375
LY3009120 resistant cells, referring to A375-RLY, using the
method described (Yadav et al., 2012). As shown in Figure S4C,
A375-RLY cells were resistant to LY3009120 with IC50 over
20 mM. These cells were also resistant to trametinib with IC50
of 1,042 nM, over 1,000-fold change (Figure S4D). Mechanistic
analysis revealed that MAPK reactivation and enhanced phos-
pho-AKT were parts of the resistant mechanism (Figure S4E).
Further studies to elucidate the mechanism of MAPK reactiva-
tion and phospho-AKT activation in these resistant cells are
ongoing.
LY3009120 Induces Cell Cycle G0/G1 Arrest in RAS or
BRAF Mutant Tumor Cells
As revealed in Figure 6A, treatment of BRAF V600E A375 mela-
noma cells by LY3009120 for 24 hr predominantly induced a G0/
G1 arrest with more than 95% cells in G0/G1 phase. Cells treated
for 72 hrmaintained in G0/G1 phase with a 7%–10%of cell death.
InNRASmutantSKMel-2 cells, LY3009120at 0.1or 1mMinduced
a G0/G1 arrest, but also trigged rapid cell death as early as 24 hr
(Figure6B).Seventy-twohour treatment causedevenmore signif-
icant cell death with 43% and 88% cell death at 0.1 and 1 mM,
respectively. In HCT116 cells with KRAS mutation, treatment of
cells by LY3009120 for 24 hr initially caused a predominantly
G0/G1 arrest. However, when treatment was extended to 72 hr,
it induced significant apoptosis with cell death of 61% and 83%
at 0.5 or 1 mM, respectively (Figure 6C). The apoptotic effects
were further verified by LY3009120-induced increases of cleaved
PARP in all three cell lines (Figure 6D). As a comparative study,we
also investigated cell cycle and apoptotic effects of vemurafenib
on A375, SK-Mel2, and HCT116 cells. As illustrated in Figure S5,
vemurafenib at 0.1 and 1 mM induced a predominant G0/G1 arrest
in A375 cells, similar to LY3009120. However, it had no significant
effectoncell cycleorapoptosisup to10mMineitherNRASmutantcer Cell 28, 384–398, September 14, 2015 ª2015 Elsevier Inc. 391
Figure 5. Activity Profiles of LY3009120 and Trametinib
(A and B) Relationship of genetic mutation and sensitivity to LY3009120 across 514 cell lines (A) or trametinib across 233 cell lines (B). The FDR for the association
is plotted in rank order from most significant associations at the right. Red and green bars indicate mutations associated with resistance and sensitivity,
respectively, to LY3009120 or trametinib. Mutations were analyzed individually and as groups, e.g., ‘‘KRAS+NRAS+HRAS’’ indicates cells with a mutation in any
of these genes.
(C and D) Growth inhibition of the parental (black curve) and trametinib-resistant (red curve) A375 cells by trametinib (C) and LY3009120 (D).
(E) Immunoblot analysis of the indicated proteins in the parental A375 cells and in trametinib-resistant A375-RM cells.
See also Figure S4 and Table S5.
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SK-Mel2 orKRASmutant HCT116cells, consistent with its lack of
activity in NRAS or KRASmutant cells.
Anti-tumor Activities of LY3009120 in BRAF V600E,
KRAS, or NRAS Mutant Models
As illustrated in Figure 7A, a single dose oral treatment of nude
rats bearing A375 xenograft tumors with LY3001920 from 3 to
50 mg/kg showed a dose-dependent inhibition of phospho-
MEK and -ERK, and the calculated dose for 50% inhibition of
phospho-ERK (ED50) was 4.36 mg/kg (Figure 7B), with plasma
concentration to achieve 50% inhibition (EC50) of 68.9 ng/ml
or 165 nM. This pharmacokinetics (PK) and pharmacodynamics
(PD) relationship translated into anti-tumor growth activity in this
model. As demonstrated in Figure 7C, oral treatment of animals
bearing xenograft tumors by 5, 10, or 15 mg/kg, twice daily (BID)
of LY3009120, induced a dose-dependent tumor growth inhibi-
tion and regression. To further confirm and compare anti-tumor
activities of LY3001920 and vemurafenib in BRAF V600E mela-
noma model, we tested both compounds in a PDX melanoma
model with a BRAF V600E mutation. As shown in Figure 7D,
oral treatment of nude rats bearing PDX tumors with either 15
or 30 mg/kg LY3009120 showed near complete tumor regres-
sion. Similarly, vemurafenib at 20 mg/kg BID also showed signif-
icant tumor growth inhibition, suggesting that both LY3009120
and vemurafenib are effective for treatment of melanoma tumors
with BRAF V600E mutation. However, LY3009120 exhibited
more prolonged inhibition of tumor growth after cessation of
drug dosing in this model.
In KRAS G13D HCT116 colorectal tumor model, when tumors
were well established and grown to 800 mg, LY3009120 was
administered orally at 30 mg/kg BID for over 3 weeks, and signif-
icant tumor growth inhibition was observed (Figure 7E). In a
KRAS Q61K Calu6 lung tumor model, treatment of LY3009120
at 30 mg/kg BID displayed tumor growth regression, and the tu-
mor growth delay was persistent even after treatment was with-
drawn (Figure 7F). Similarly, inNRASQ61K SKMel-30melanoma
model, LY3009120 at 15 or 30 mg/kg BID showed dose-depen-
dent tumor growth inhibition (Figure 7G). Altogether, these in vivo
efficacy studies suggest that LY3009120 is active at inhibiting tu-
mor growth with KRAS or NRAS mutation.
The tolerability of LY3009120 was carefully evaluated in all
preclinical pharmacology studies. In rat xenograft studies pre-
sented in this paper, no toxicity sign or significant body weight
loss was observed through the entire studies when LY3009120
was dosed up to 30 mg/kg twice daily for 21 (Figures S6A–
S6C) or 28 days (Figure S6D). LY3009120 was observed to
be well tolerated in in vivo efficacy studies based on body
weight changes. From a PK standpoint, when LY3009120
was dosed in rat and dog with a conventional suspension
formulation, the oral bioavailability was <4%. In an effort to in-
crease exposure, a solid spray dried dispersion (SDD) formula-
tion using PVP-VA (vinylpyrrolidone/vinylacetate) copolymer
was investigated and tested in dogs and rats to evaluate PK
properties. In both rat and dog, the solid dispersion provided
higher exposure and oral bioavailability than conventional
suspension formulation. Exposure increased across the dose
range tested (10 to 100 mg/kg) in a dose-dependent manner
with an estimated oral bioavailability of 55.4% in rats and
16.7% in dogs. This PK profile of LY3009120 supportsCancontinued use of solid dispersion as the initial formulation for
clinical development.
DISCUSSION
Selective BRAF inhibitors vemurafenib and dabrafenib paradox-
ically activate downstream signaling, promote tumor growth
in the WT BRAF cells, and are contraindicated for treatment of
cancer patients whose tumors harbor a RAS mutation. Recent
studies have revealed that BRAF inhibitors promote BRAF and
CRAF dimerization, an essential step in paradoxical activation.
However, the exact mechanism of paradoxical activation is still
in debate. Crystal structures of BRAF in complex with vemurafe-
nib and its analog PLX4720 revealed an asymmetric dimer in
which only one of the two ATP sites was effectively occupied
by the drug (Bollag et al., 2010, 2012; Tsai et al., 2008). By bind-
ing to one RAF subunit and promoting dimer formation, the
BRAF selective inhibitors activate the second drug-free partner,
by either altering subcellular localization or propagating a con-
formational change to the drug-free protomer (Heidorn et al.,
2010; Poulikakos et al., 2010). Based on the outlined model,
we hypothesized that in order to block paradoxical activation,
a RAF inhibitor must effectively inhibit not only all RAF isoforms,
but also the active RAF homo- and hetero-dimers. LY3009120 is
a pan-RAF inhibitor with activities against three RAF isoforms
and RAF dimers. Whereas the anti-tumor activity of vemurafenib
and dabrafenib is primarily restricted to BRAF mutant cells,
LY3001920 additionally inhibits the growth of tumors with
NRAS or KRASmutations. Therefore, LY3009120 has the poten-
tial for treatment of cancer patients having tumors with RAS or
BRAF mutations.
All RAF inhibitors tested in our studies induce RAF dimeriza-
tion, and LY3009120 induces a more significant dimerization
compared to vemurafenib or dabrafenib in our studies. However,
LY3009120 is able to inhibit the downstream phosphorylation of
MEK and ERK at the same concentrations that induce dimers.
This suggests that the magnitude of compound-induced
dimerization does not correlate with its induction of paradoxical
activation. To shed light on the nature of this phenomenon, we
evaluated the binding modes of certain RAF inhibitors. Based
on the structural analysis, type I inhibitor SB590885 binds to
the RAF protein in an aC-helix-in and DFG-in conformation,
type IIb inhibitors vemurafenib and dabrafenib bind to an aC-he-
lix-out and DFG-in conformation, and type IIa inhibitors, such as
TAK-632, AZD628, and sorafenib bind to an aC-helix-in and
DFG-out conformation (Wang and Kim, 2012). We postulate
that the binding mode of an inhibitor can affect RAF dimerization
and paradoxical activation. Further structural analysis revealed
that inhibitors that bind to the kinase in the aC-helix-in conforma-
tion, including type I inhibitor SB590885 and type IIa inhibitors
LY3009120, AZ628, and TAK-632 stabilize the side-to-side
dimeric arrangement. Conversely, binding of type IIb inhibitors
(such as vemurafenib or dabrafenib) causes movement of the
aC-helix to the out orientation that disfavors the dimer formation
by disrupting the Arg506-Asp449 salt bridge and positioning
positively-charged Arg506 from the other protomer in the dimer
(Figure S2H). These analyses help illustrate why LY3009120 and
other type IIa inhibitors tested in our studies induce more RAF
dimerization. In line with this structural model, the mutation ofcer Cell 28, 384–398, September 14, 2015 ª2015 Elsevier Inc. 393
(legend on next page)
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Figure 7. Anti-tumor Activities of LY3009120
in BRAF V600E or RAS Mutant Xenograft
Models
(A) Western blot analysis of phospho-MEK
and -ERK in BRAF V600E A375 xenograft tumors
2hr after the tumor-bearing rats treatedwitha single
administration of LY3009120 at indicated doses.
(B) The phospho-ERK level from rats treated as in
(A) (2 hr post-treatment) was determined by MSD
ELISA. The ED50 is the dose to achieved 50%
target inhibition.
(C) Anti-tumor growth activities of LY3009120 in
melanoma BRAF V600E A375 rat xenograft model.
Vehicle, black line; LY3009120 5 mg/kg BID, pur-
ple line; LY3009120 10 mg/kg BID, orange line;
LY3009120 15 mg/kg BID, blue line; LY3009120
20 mg/kg BID 3 7 days, 1 week off, BID 3 7,
green line. The red line under the x axis indicates
the drug dosing period. Error bar, ±SEM.
(D) Anti-tumor growth activities of LY3009120 and
vemurafenib in a melanoma PDX model carrying a
BRAF V600E mutation. Vehicle, black line; vemur-
afenib 20 mg/kg BID, purple line; LY3009120
15 mg/kg BID, blue line; LY3009120 30 mg/kg BID,
red line. The red line under the x axis indicates the
drug dosing period. Error bar ± SEM.
(E–G) Anti-tumor growth activities of LY3009120
in HCT116 (E), Calu6 (F), and SK-Mel30 (G) rat
xenograft models. Vehicle, black line; LY3009120
15 mg/kg BID, blue line; LY3009120 30mg/kg BID,
red line. The red lines under the x axis indicates the
drug dosing period. Error bars, ±SEM.
See also Figure S6.Arg506 at the dimer interface was shown to reduce dimer forma-
tion (Baljuls et al., 2011; Rajakulendran et al., 2009). Further vali-
dating this model, type I Raf inhibitor SB590885, which also
binds to aC-helix-in conformation, induces BRAF-CRAF hetero-
dimers andCRAF homodimers significantly in luciferase comple-
mentation assays. In contrast to LY3009120, SB590885 induced
significant paradoxical activation in RAS mutant cells (Figures
S2F and S2G).
LY3009120 induces minimal paradoxical activation due to its
unique properties. First, it inhibits all three RAF isoforms with
similar affinity as revealed by biochemical and cellular analyses,Figure 6. LY3009120 Induces Cell Cycle G0/G1 Arrest and Apoptosis in Tumor Cells with BRAF
(A–C) Flow cytometry cell-cycle analysis of BRAF V600E mutant A375 cells (A), NRAS mutant SK-Mel2 cells
LY3009120 for 24 or 72 hr. *Indicates 0.5 mM of LY3009120 treatment.
(D) Immunoblot analysis for phospho-MEK and -ERK and cleaved PARP (cPARP) in tumor cells after 1 mM
See also Figure S5.
Cancer Cell 28, 384–398, Sewhereas vemurafenib and dabrafenib
have minimal to weak CRAF inhibition
compared to their BRAF activities. As
both BRAF and CRAF are involved in par-
adoxical activation, the cellular pan-RAF
activities are important for a RAF inhibitor
to reduce paradoxical activation (Hatzi-
vassiliou et al., 2010; Heidorn et al.,
2010). Second, LY3009120 inhibits the
activities of BRAF/CRAF heterodimerand BRAF or CRAF homodimers via its effective occupancy of
both protomers in the dimer. We have shown that LY3009120
inhibits the downstream signaling of different RAF dimers,
and the crystal structure of BRAF revealed that LY3009120
occupies both RAF protomers. Conversely, crystal structure
of vemurafenib revealed an asymmetric dimer in which only
one protomer is occupied (Bollag et al., 2010, 2012). Third,
the unique binding to DFG-out inactive conformation of
LY3009120 may contribute to its reduced paradoxical activa-
tion. As suggested by Bollag et al. (2012), a RAF inhibitor
with a different binding conformation from vemurafenib mightV600E, NRAS, or KRAS Mutation
(B), and KRAS mutant HCT116 cells (C) treated by
LY3009120 treatment.
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be required for a RAF inhibitor to effectively occupy both asym-
metric protomers in the RAF dimers. Our crystal structural anal-
ysis revealed that LY3009120 favors a DFG-out conformation
that may support the reason that LY3009120 is able to bind
both protomers simultaneously. This DFG-out binding confor-
mation is similar to TAK-632, which indeed shows occupancy
of two ATP binding sites and minimal paradoxical activation
(Nakamura et al., 2013; Okaniwa et al., 2013). Additionally,
the crystal structure of PLX-4720 with BRAF also suggests
that a type IIa inhibitor binding to DFG-out conformation may
be required for complete occupancy of the two protomers
(Tsai et al., 2008). Overall, the cellular pan-RAF and RAF dimer
inhibitory activities, the two site occupancy, and the aC-helix-
in/DFG-out binding conformation of LY3009120 support its
induction of RAF dimerization and inhibition of paradoxical
activation.
Although the RAF pathway has been a subject of intense
investigation for many years, the exact mechanisms whereby
RAF is activated in response to growth factors and oncogenic
RAS or BRAF mutations remain elusive. Recent studies sug-
gested that BRAF V600E functions as a monomer that signals
in the absence of RAF dimerization (Poulikakos et al., 2011). In
contrast to BRAF V600E, RAF dimerization is required for normal
RAS-dependent RAF activation and biological function of dis-
ease-associated RAS or atypical BRAF mutation (Farrar et al.,
1996; Freeman et al., 2013; Luo et al., 1996; Rajakulendran
et al., 2009; Wan et al., 2004). Indeed, the R509H mutation leads
to the abolishment of RAF dimerization and activation (Hatzivas-
siliou et al., 2010). A recent study revealed that the RAF dimer
is functionally asymmetric with one kinase unit acting as an acti-
vator stimulating activity of the partner, receiver kinase (Hu et al.,
2013). Overall, in order to block the RAF activities in different
cellular backgrounds, it is required for a RAF inhibitor to effec-
tively inhibit the kinase activities of RAF monomer and active
dimers. LY3009120 effectively inhibits not only BRAF V600E
monomer but also different active RAF dimers, thus is capable
of inhibiting the phospho-MEK and ERK in different genetic
backgrounds.
In melanoma, LY3009120 is active against BRAF or NRAS
mutant cells, as well as selective BRAF inhibitor resistant cells
due to MAPK reactivation, BRAF splicing or NRAS mutation.
Recently, pan-RAF and SRC dual inhibitors were also identified
to be effective for BRAF resistant melanoma (Girotti et al.,
2015). More importantly, LY3009120 has shown activities for
many KRAS mutant tumor cells, including lung, colorectal and
pancreatic tumor cells in vitro and in vivo. However, some RAS
mutant or even BRAFmutant cells are less sensitive or resistant
to LY3009120. This is likely due to other accompanying molecu-
lar alterations such as RB1, TP53, and PI3K/AKT pathway muta-
tions. It is also likely that KRASmutation may not be the primary
oncogenic driver in some of these tumor cells as previously
demonstrated (Scholl et al., 2009), or in some RASmutant cells,
dysregulation of other signaling pathways, such as RelA/B and
PI3K pathways are important in addition to MAPK signaling (Hal-
ilovic et al., 2010; Wee et al., 2009). Therefore, for targeting RAS
mutant cancers, a combination approach is potentially more
desirable. The clinical activities of LY3009120 for the treatment
of cancer patients with RAS or BRAF mutation are currently in
clinical investigation.396 Cancer Cell 28, 384–398, September 14, 2015 ª2015 Elsevier InEXPERIMENTAL PROCEDURES
Kinase Activity Measurement Using KiNativ Assays of ActivX
Biosciences
Whole cell KiNativ assays were developed by ActivX Biosciences using whole
cell lysates of A375 cells as described (Patricelli et al., 2011).
In Vitro Kinase Assays with Native RAF Proteins Prepared by IP
RAF proteins were immunoprecipitated using 1.5 mg Dynabead protein G
beads (Novex), 500 mg cell lysate, and 2 mg of anti-RAF antibody. The IP-pre-
pared protein was recovered with 150 ml of lysis buffer (Thermo Scientific).
For the kinase assay, 10 ml of IP protein, 20 ml of magnesium/ATP cocktail,
1 mg of MEK1(K97R) protein, and 10 ml of Assay Dilution Buffer (Millipore)
were mixed together followed by incubation at 30C with shaking for
30 min. Then 20 ml 33 SDS sample buffer was added to stop the reaction.
The reaction mixtures were subjected for western blot analysis with phos-
pho-MEK antibody.
Transfections
A375 cells were transfected with pcDNA3.1 plasmid encoding BRAF V600E
(deleted amino acids 169–380)-Myc protein (p61BRAF) using Fugene 6 per
manufacturer’s instruction. Individual G418 resistant clones were evaluated
for expression of BRAF and Myc-tagged protein.
MSD ELISA Analysis of Phospho-ERK Activity
The ELISA analysis of phospho-ERK activity was determined with Meso Scale
Discovery (MSD) ERK1 and ERK2 Duplex V.2 MD6000 4 Spot Plate and assay
Kit (N41CB-1) per manufacturer’s instructions.
Animal Studies
To evaluate in vivo efficacy of LY3009120, multiple xenograft tumor models
were utilized. Briefly, 5–10 3 106 tumor cells in a 1:1 Matrigel mix (0.2 ml total
volume) were injected subcutaneously into the right hind flank of female NIH
nude rats (Taconic Biosciences). After allowing tumors to reach a desired size
of 300–500 mm3, animals were randomized into either groups of eight for
efficacy studies or groups of three to four for PK/PD studies. All animal ex-
periments were approved and performed in accordance with American Asso-
ciation for Laboratory Animal Care institutional guidelines and monitored by
the Eli Lilly and Company Animal Care and Use Committee. Melanoma
PDX model (ST052B) was established at START (South Texas Accelerated
Therapeutics, San Antonio, TX) from a patient tissue with the patient consent
and approval by the Institutional Review Board of Ethics Committee of
START. LY3009120 was administered via oral gavage (PO) twice daily at indi-
cated doses. Tumor growth and body weight were monitored over time to
evaluate efficacy and signs of toxicity as described (Yadav et al., 2014).
For PK and exposure analysis, LY3009120 was administered orally or intra-
venously through tail vein, and the plasma concentrations were determined
by high-pressure liquid chromatography-mass spectrometry (HPLC-MS)
analysis.
Statistical Methods
To test the significance of the association between genomics and compound
efficacy across tumor cell panels, we applied a modified Tobit regression
model (Tobin, 1958) correcting for the right censoring nature of the compound
sensitivity measurement. In the analyses of drug sensitivity, we modified this
model to make it more flexible, allowing a variable threshold value that may
change among samples. A Log10 likelihood ratio (LOD) is computed by
comparing each genemodel to the ‘‘null model’’ without any gene information.
See Supplemental Experimental Procedures for cell lines, antibodies, re-
agents, enzymatic kinase assays, detection of RAF dimerization by luciferase
complementation assays, crystallization, X-ray data collection, and structure
determination.
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